Titre : Mépacrine

Mépacrine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Semantic Web
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mépacrine : Questions médicales les plus fréquentes", "headline": "Mépacrine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mépacrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-23", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mépacrine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Aminoacridines", "url": "https://questionsmedicales.fr/mesh/D000609", "about": { "@type": "MedicalCondition", "name": "Aminoacridines", "code": { "@type": "MedicalCode", "code": "D000609", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.046.250" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Moutarde de quinacrine", "alternateName": "Quinacrine Mustard", "url": "https://questionsmedicales.fr/mesh/D011797", "about": { "@type": "MedicalCondition", "name": "Moutarde de quinacrine", "code": { "@type": "MedicalCode", "code": "D011797", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.046.250.760.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Mépacrine", "alternateName": "Quinacrine", "code": { "@type": "MedicalCode", "code": "D011796", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Chanakya Nath Kundu", "url": "https://questionsmedicales.fr/author/Chanakya%20Nath%20Kundu", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India. cnkundu@kiitbiotech.ac.in." } }, { "@type": "Person", "name": "Thomas R Lane", "url": "https://questionsmedicales.fr/author/Thomas%20R%20Lane", "affiliation": { "@type": "Organization", "name": "Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA." } }, { "@type": "Person", "name": "Sean Ekins", "url": "https://questionsmedicales.fr/author/Sean%20Ekins", "affiliation": { "@type": "Organization", "name": "Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA peter.madrid@sri.com sean@collaborationspharma.com." } }, { "@type": "Person", "name": "Biswajit Das", "url": "https://questionsmedicales.fr/author/Biswajit%20Das", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India." } }, { "@type": "Person", "name": "Chinmayee Sethy", "url": "https://questionsmedicales.fr/author/Chinmayee%20Sethy", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The SIB Swiss Institute of Bioinformatics Semantic Web of data.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37878411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/nar/gkad902" } }, { "@type": "ScholarlyArticle", "name": "Investigating the potential of the semantic web for education: Exploring Wikidata as a learning platform.", "datePublished": "2023-03-13", "url": "https://questionsmedicales.fr/article/37361737", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10639-023-11664-1" } }, { "@type": "ScholarlyArticle", "name": "Semantic Analysis and Topic Modelling of Web-Scrapped COVID-19 Tweet Corpora through Data Mining Methodologies.", "datePublished": "2022-05-10", "url": "https://questionsmedicales.fr/article/35628018", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/healthcare10050881" } }, { "@type": "ScholarlyArticle", "name": "CAENet: Contrast adaptively enhanced network for medical image segmentation based on a differentiable pooling function.", "datePublished": "2023-10-17", "url": "https://questionsmedicales.fr/article/37918260", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.compbiomed.2023.107578" } }, { "@type": "ScholarlyArticle", "name": "Automatic transparency evaluation for open knowledge extraction systems.", "datePublished": "2023-08-31", "url": "https://questionsmedicales.fr/article/37653549", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13326-023-00293-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérocycliques 3 noyaux", "item": "https://questionsmedicales.fr/mesh/D006575" }, { "@type": "ListItem", "position": 5, "name": "Acridines", "item": "https://questionsmedicales.fr/mesh/D000166" }, { "@type": "ListItem", "position": 6, "name": "Aminoacridines", "item": "https://questionsmedicales.fr/mesh/D000609" }, { "@type": "ListItem", "position": 7, "name": "Mépacrine", "item": "https://questionsmedicales.fr/mesh/D011796" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mépacrine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mépacrine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mépacrine", "description": "Comment diagnostiquer une infection nécessitant la mépacrine ?\nQuels tests sont utilisés pour la mépacrine ?\nLa mépacrine est-elle utilisée pour des maladies spécifiques ?\nQuels symptômes indiquent un besoin de mépacrine ?\nComment évaluer l'efficacité de la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mépacrine", "description": "Quels sont les effets secondaires courants de la mépacrine ?\nLa mépacrine peut-elle provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose de mépacrine ?\nLa mépacrine affecte-t-elle le système digestif ?\nQuels signes d'infection nécessitent un traitement par mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mépacrine", "description": "Comment prévenir les infections traitées par mépacrine ?\nLes voyages dans certaines zones augmentent-ils le risque d'infection ?\nDes vaccins existent-ils pour prévenir les infections ?\nComment réduire le risque de piqûres de moustiques ?\nLa mépacrine peut-elle être utilisée en prévention ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mépacrine", "description": "Comment la mépacrine est-elle administrée ?\nQuelle est la posologie standard de mépacrine ?\nLa mépacrine est-elle efficace contre tous les parasites ?\nPeut-on combiner la mépacrine avec d'autres traitements ?\nQuels sont les traitements alternatifs à la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mépacrine", "description": "Quelles complications peuvent survenir avec la mépacrine ?\nLa mépacrine peut-elle causer des problèmes hématologiques ?\nQuels signes indiquent une complication grave ?\nComment gérer les complications liées à la mépacrine ?\nLes complications sont-elles fréquentes avec la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mépacrine", "description": "Quels facteurs augmentent le risque d'infection ?\nL'âge influence-t-il le risque d'effets secondaires ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe sexe influence-t-il la réponse à la mépacrine ?\nLes interactions médicamenteuses sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Semantic+Web&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection nécessitant la mépacrine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests de laboratoire pour identifier les parasites." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour la mépacrine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de selles peuvent être effectués." } }, { "@type": "Question", "name": "La mépacrine est-elle utilisée pour des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour traiter la leishmaniose et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de mépacrine ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fièvre, des douleurs abdominales et des éruptions cutanées peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité de la mépacrine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des symptômes et des résultats de tests de suivi." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la mépacrine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des nausées, des vomissements et des éruptions cutanées." } }, { "@type": "Question", "name": "La mépacrine peut-elle provoquer des réactions allergiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions allergiques comme des démangeaisons ou un gonflement peuvent survenir." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose de mépacrine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de surdose incluent des vertiges, des troubles de la vision et des convulsions." } }, { "@type": "Question", "name": "La mépacrine affecte-t-elle le système digestif ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut causer des troubles digestifs comme des douleurs abdominales et des diarrhées." } }, { "@type": "Question", "name": "Quels signes d'infection nécessitent un traitement par mépacrine ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs abdominales sévères et de la fièvre persistante peuvent nécessiter un traitement." } }, { "@type": "Question", "name": "Comment prévenir les infections traitées par mépacrine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut des mesures d'hygiène, l'utilisation de moustiquaires et des vaccins." } }, { "@type": "Question", "name": "Les voyages dans certaines zones augmentent-ils le risque d'infection ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones endémiques augmente le risque d'infections parasitaires." } }, { "@type": "Question", "name": "Des vaccins existent-ils pour prévenir les infections ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccins sont disponibles pour certaines infections, mais pas pour toutes." } }, { "@type": "Question", "name": "Comment réduire le risque de piqûres de moustiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des répulsifs, porter des vêtements longs et installer des moustiquaires." } }, { "@type": "Question", "name": "La mépacrine peut-elle être utilisée en prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Elle n'est généralement pas utilisée en prévention, mais plutôt en traitement actif." } }, { "@type": "Question", "name": "Comment la mépacrine est-elle administrée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La mépacrine est généralement administrée par voie orale sous forme de comprimés." } }, { "@type": "Question", "name": "Quelle est la posologie standard de mépacrine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie selon l'infection, mais elle est souvent de 100 à 200 mg par jour." } }, { "@type": "Question", "name": "La mépacrine est-elle efficace contre tous les parasites ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement efficace contre certains parasites comme ceux de la leishmaniose." } }, { "@type": "Question", "name": "Peut-on combiner la mépacrine avec d'autres traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être combinée avec d'autres médicaments selon la maladie traitée." } }, { "@type": "Question", "name": "Quels sont les traitements alternatifs à la mépacrine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des alternatives incluent l'antimoniate de méglumine et d'autres antiparasitaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la mépacrine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles hépatiques et des réactions cutanées sévères." } }, { "@type": "Question", "name": "La mépacrine peut-elle causer des problèmes hématologiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des troubles sanguins comme l'anémie ou la thrombocytopénie." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des saignements inhabituels ou des douleurs abdominales sévères doivent alerter." } }, { "@type": "Question", "name": "Comment gérer les complications liées à la mépacrine ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'arrêt du médicament et un suivi médical approprié." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec la mépacrine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent un système immunitaire affaibli, des voyages dans des zones à risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'effets secondaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus sensibles aux effets secondaires de la mépacrine." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies hépatiques ou sanguines augmentent le risque." } }, { "@type": "Question", "name": "Le sexe influence-t-il la réponse à la mépacrine ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que le sexe peut influencer la pharmacocinétique de la mépacrine." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent augmenter les effets secondaires ou réduire l'efficacité." } } ] } ] }

Sources (5108 au total)

Automatic transparency evaluation for open knowledge extraction systems.

This paper proposes Cyrus, a new transparency evaluation framework, for Open Knowledge Extraction (OKE) systems. Cyrus is based on the state-of-the-art transparency models and linked data quality asse... In Cyrus, data transparency includes ten dimensions which are grouped in two categories. In this paper, six of these dimensions, i.e., provenance, interpretability, understandability, licensing, avail... This is the first research to study the transparency of OKE systems that provides a comprehensive set of transparency dimensions spanning ethics, trustworthy AI, and data quality approaches to transpa...

Hospital admission after primary care consultation for community-onset lower urinary tract infection: a cohort study of risks and predictors using linked data.

Urinary tract infections (UTIs) are a common indication for antibiotic prescriptions, reductions in which would reduce antimicrobial resistance (AMR). Risk stratification of patients allows reductions... To identify risk factors for hospital admission following UTI, to inform targeted antibiotic stewardship.... Retrospective cohort study of East London primary care patients.... Hospital admission outcomes following primary care consultation for UTI were analysed using linked data from primary care, secondary care, and microbiology, from 1 April 2012 to 31 March 2017. The out... Of the 169 524 episodes of UTI, UHA occurred in 1336 cases (0.8%, 95% confidence interval [CI] = 0.7 to 0.8) and AHA in 6516 cases (3.8%, 95% CI = 3.8 to 3.9). On multivariable analysis, increased odd... Urinary infection-related hospital admission after primary care consultation for community-onset lower UTI was rare; however, increased odds for UHA were observed for some patient groups. Efforts to r...

Mortality and cause of death during inpatient psychiatric care in New South Wales, Australia: A retrospective linked data study.

Premature mortality in people with mental illness is well-documented, yet deaths during inpatient psychiatric care have received little research attention. This study investigates mortality rates and ... A retrospective cohort study using linked administrative datasets with complete capture of psychiatric admissions in NSW from 2002 to 2012 (n = 421,580) was conducted. Univariate and multivariate rand... The mortality rate during inpatient psychiatric care was 1.12 deaths per 1000 episodes of care and appeared to decline over the study period. Suicide accounted for 17% of inpatient deaths, while physi... The mortality rate and number of avoidable deaths during inpatient psychiatric care were substantial and warrant further systemic investigation. This was driven by a dual burden of physical health con...

Did the UK's public health shielding policy protect the clinically extremely vulnerable during the COVID-19 pandemic in Wales? Results of EVITE Immunity, a linked data retrospective study.

The UK shielding policy intended to protect people at the highest risk of harm from COVID-19 infection. We aimed to describe intervention effects in Wales at 1 year.... Retrospective comparison of linked demographic and clinical data for cohorts comprising people identified for shielding from 23 March to 21 May 2020; and the rest of the population. Health records wer... The shielded cohort included 117,415 people, with 3,086,385 in the comparator cohort. The largest clinical categories in the shielded cohort were severe respiratory condition (35.5%), immunosuppressiv... Deaths and healthcare utilisation were higher amongst shielded people than the general population, as would be expected in the sicker population. Differences in testing rates, deprivation and pre-exis...

Relative rates of cancers and deaths in Australian communities with PFAS environmental contamination associated with firefighting foams: A cohort study using linked data.

Per- and polyfluoroalkyl substances (PFAS) are environmental contaminants that are potentially harmful to health. We examined if rates of selected cancers and causes of deaths were elevated in three A... All residents identified in the Medicare Enrolment File (1983-2019)-a consumer directory for Australia's universal healthcare-who ever lived in an exposure area (Katherine, Oakey and Williamtown), and... We observed higher rates of prostate cancer (SIR=1·76, 95 % confidence interval (CI) 1·36-2·24) in Katherine; laryngeal cancer (SIR=2·71, 95 % CI 1·30-4·98), kidney cancer (SIR=1·82, 95 % CI 1·04-2·96... There was limited evidence to support an association between living in a PFAS exposure area and risks of cancers or cause-specific deaths....